NASDAQ:CLGN CollPlant Biotechnologies (CLGN) Stock Price, News & Analysis $4.23 +0.04 (+0.95%) (As of 11/20/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends About CollPlant Biotechnologies Stock (NASDAQ:CLGN) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get CLGN alerts:Sign Up Key Stats Today's Range$3.97▼$4.4150-Day Range$3.71▼$4.9352-Week Range$3.61▼$6.99Volume9,184 shsAverage Volume17,760 shsMarket Capitalization$48.43 millionP/E RatioN/ADividend YieldN/APrice Target$11.00Consensus RatingStrong Buy Company OverviewCollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, Europe, and internationally. Its products are based on recombinant type I human collagen that is produced with its proprietary plant based genetic engineering technology. The company's products include BioInks for 3D printing of tissues and organs; dermal filler and soft tissue fillers for treating wrinkles; 3D Bioprinted breast implants for regeneration of breast tissue; VergenixSTR, a soft tissue repair matrix intended for the treatment of tendinopathy; and VergenixFG, an advanced wound care product for the treatment of deep surgical incisions and wounds, including diabetic ulcers, venous and pressure ulcers, burns, bedsores, and other chronic wounds; as well as develops injectable breast implants and 3D bioprinted regenerative soft tissue matrix for use in breast reconstruction procedures. It has collaboration agreements with Advanced Regenerative Manufacturing Institute; RegenMed Development Organization; International Society for Biofabrication; AbbVie; and STEMCELL Technologies. The company was formerly known as CollPlant Holdings Ltd. and changed its name to CollPlant Biotechnologies Ltd. in June 2019. The company was founded in 2004 and is headquartered in Rehovot, Israel.Read More… My #1 Pre IPO Trade for 2025 – NAME and TICKER (Ad)One tiny company... Could quickly become "the next SpaceX." It plans to go public on the NASDAQ. And today you can buy Pre-IPO shares for less than $4.00. Get urgent details inside this free report...The Next SpaceX Pre-IPO CollPlant Biotechnologies Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks37th Percentile Overall ScoreCLGN MarketRank™: CollPlant Biotechnologies scored higher than 37% of companies evaluated by MarketBeat, and ranked 686th out of 963 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.8 / 5Analyst RatingStrong Buy Consensus RatingCollPlant Biotechnologies has received a consensus rating of Strong Buy. The company's average rating score is 3.50, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageCollPlant Biotechnologies has received no research coverage in the past 90 days.Read more about CollPlant Biotechnologies' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for CollPlant Biotechnologies are expected to grow in the coming year, from ($1.44) to ($0.56) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of CollPlant Biotechnologies is -2.75, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of CollPlant Biotechnologies is -2.75, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCollPlant Biotechnologies has a P/B Ratio of 1.71. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about CollPlant Biotechnologies' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.20% of the float of CollPlant Biotechnologies has been sold short.Short Interest Ratio / Days to CoverCollPlant Biotechnologies has a short interest ratio ("days to cover") of 1.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in CollPlant Biotechnologies has recently increased by 6.21%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCollPlant Biotechnologies does not currently pay a dividend.Dividend GrowthCollPlant Biotechnologies does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted0.20% of the float of CollPlant Biotechnologies has been sold short.Short Interest Ratio / Days to CoverCollPlant Biotechnologies has a short interest ratio ("days to cover") of 1.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in CollPlant Biotechnologies has recently increased by 6.21%, indicating that investor sentiment is decreasing significantly. News and Social Media0.6 / 5News SentimentN/A Search Interest1 people have searched for CLGN on MarketBeat in the last 30 days. MarketBeat FollowsOnly 1 people have added CollPlant Biotechnologies to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, CollPlant Biotechnologies insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 9.60% of the stock of CollPlant Biotechnologies is held by insiders.Percentage Held by InstitutionsOnly 21.69% of the stock of CollPlant Biotechnologies is held by institutions.Read more about CollPlant Biotechnologies' insider trading history. Receive CLGN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for CollPlant Biotechnologies and its competitors with MarketBeat's FREE daily newsletter. Email Address CLGN Stock News HeadlinesCOLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR 2024 THIRD QUARTER FINANCIAL RESULTS AND CONFERENCE CALL INFORMATIONNovember 12, 2024 | prnewswire.comCompanies Like CollPlant Biotechnologies (NASDAQ:CLGN) Can Afford To Invest In GrowthNovember 9, 2024 | finance.yahoo.comTrump’s IRS Hands Massive ‘Victory Gift’ To 401K OwnersTrump quietly left open an "off the books" wealth-protection loophole hidden in the 6,871 pages of the IRS Tax Code… And since then… "In the know" patriots have quietly used this same "Trump revenge loophole" to shield their life savings from Bidenomics…November 21, 2024 | Colonial Metals (Ad)CollPlant Biotechnologies (NASDAQ:CLGN) Stock Quotes, Forecast and News SummaryOctober 13, 2024 | benzinga.comCollPlant Biotechnologies Ltd. (CLGN) Q2 2024 Earnings Call TranscriptAugust 21, 2024 | seekingalpha.comCracking The Code: Understanding Analyst Reviews For CollPlant BiotechnologiesAugust 21, 2024 | benzinga.comCollPlant Biotechnologies Ltd. (NASDAQ:CLGN) Q2 2024 Earnings Call TranscriptAugust 21, 2024 | msn.comCollPlant Biotechnologies Posts Loss In Q2 - Quick FactsAugust 20, 2024 | markets.businessinsider.comSee More Headlines CLGN Stock Analysis - Frequently Asked Questions How have CLGN shares performed this year? CollPlant Biotechnologies' stock was trading at $6.39 at the beginning of 2024. Since then, CLGN shares have decreased by 33.8% and is now trading at $4.23. View the best growth stocks for 2024 here. How were CollPlant Biotechnologies' earnings last quarter? CollPlant Biotechnologies Ltd. (NASDAQ:CLGN) issued its quarterly earnings results on Thursday, August, 24th. The company reported $0.49 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.34) by $0.83. The business earned $10.18 million during the quarter, compared to analyst estimates of $0.26 million. CollPlant Biotechnologies had a negative net margin of 2,535.70% and a negative trailing twelve-month return on equity of 65.98%. When did CollPlant Biotechnologies IPO? CollPlant Biotechnologies (CLGN) raised $22 million in an initial public offering (IPO) on Friday, December 9th 2016. The company issued 3,500,000 shares at a price of $6.23 per share. Ladenburg Thalmann served as the underwriter for the IPO and Roth Capital Partners was co-manager. Who are CollPlant Biotechnologies' major shareholders? CollPlant Biotechnologies' top institutional shareholders include Villere ST Denis J & Co. LLC (4.23%), Pinnacle Associates Ltd. (4.09%) and Benjamin Edwards Inc. (0.21%). How do I buy shares of CollPlant Biotechnologies? Shares of CLGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of CollPlant Biotechnologies own? Based on aggregate information from My MarketBeat watchlists, some other companies that CollPlant Biotechnologies investors own include Enovix (ENVX), Rambus (RMBS), COMPASS Pathways (CMPS), Ginkgo Bioworks (DNA), Globant (GLOB), Luminar Technologies (LAZR) and Saia (SAIA). Company Calendar Last Earnings8/24/2023Today11/21/2024Next Earnings (Confirmed)11/27/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical appliances & supplies Sub-IndustryMedical Equipment Current SymbolNASDAQ:CLGN CUSIPN/A CIK1631487 Webwww.collplant.com Phone972732325600Fax972-73-232-5602Employees70Year FoundedN/APrice Target and Rating Average Stock Price Target$11.00 High Stock Price Target$11.00 Low Stock Price Target$11.00 Potential Upside/Downside+160.0%Consensus RatingStrong Buy Rating Score (0-4)3.50 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($1.54) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-7,020,000.00 Net Margins-2,535.70% Pretax Margin-2,535.70% Return on Equity-65.98% Return on Assets-54.37% Debt Debt-to-Equity RatioN/A Current Ratio6.27 Quick Ratio6.14 Sales & Book Value Annual Sales$10.96 million Price / Sales4.42 Cash FlowN/A Price / Cash FlowN/A Book Value$2.47 per share Price / Book1.71Miscellaneous Outstanding Shares11,450,000Free Float10,355,000Market Cap$48.43 million OptionableOptionable Beta0.44 A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for December 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report This page (NASDAQ:CLGN) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored24/7 Automated Profits in CryptoThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | SponsoredBut another coin could soar even higher …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin co...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CollPlant Biotechnologies Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share CollPlant Biotechnologies With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.